AVI funding, obtained by Tyris Therapeutics, enables to validate the synthetic DNA to develop Gene Therapies

Tyris Therapeutics, a Valencian company dedicated to the development of gene therapies for rare diseases using synthetic DNA, was selected in 2021 by the Valencian Innovation Agency (AVI) in the value consolidation program 2021-2023.

Gene therapy has experienced exponential growth in recent years, demonstrating its value in the treatment of hitherto incurable diseases. In most cases, DNA is the basis for these advanced therapies; however, current production processes are neither fast enough nor precise enough to meet the needs of today’s market, making DNA the bottleneck for the development of new gene therapies. Synthetic DNA is postulated as the solution to the problem, allowing not only large-scale production in the shortest possible time, but also increasing the safety of treatments by not containing unwanted sequences such as procaryotic or antibiotic resistance sequences.

The funded project has demonstrated the usefulness of synthetic DNA as an alternative to plasmid DNA in the development of gene therapies, specifically for the treatment of Hemophilia A.

La financiación de la AVI, obtenida por Tyris Therapeutics, permite validar el ADN sintético en el desarrollo de Terapias Génicas.

Tyris Therapeutics, empresa valenciana dedicada al desarrollo de terapias génicas para enfermedades raras empleando ADN sintético, fue seleccionada en 2021 por la Agencia Valenciana de Innovación (AVI) en el programa de consolidación de valor 2021-2023.

La terapia génica ha experimentado un crecimiento exponencial durante los últimos años, demostrando su valía en el tratamiento de enfermedades incurables hasta el momento. En la mayor parte de los casos, el ADN es la base de estas terapias avanzadas; sin embargo, los procesos de producción actual no son ni lo suficientemente rápidos ni precisos para cubrir las necesidades del mercado actual, haciendo que el ADN se ha ya convertido en el cuello de botella para el desarrollo de nuevas terapias génicas. El ADN sintético se postula como la solución al problema, permitiendo no sólo la producción a gran escala y en plazos mínimos de tiempo sino también incrementar la seguridad de los tratamientos al no contener secuencias indeseadas como las de resistencia antibióticos o procariotas.

El proyecto financiado ha permitido demostrar la utilidad del DNA sintético como alternativa al DNA plasmídico en el desarrollo de terapias génicas, concretamente para el tratamiento de Hemofilia A.

About Tyris

Founded in 2020, and fully owned by Columbus Venture Partners (columbusvp.com), Tyris Therapeutics SL is a privately held, fully integrated non-viral DNA-based gene therapy company dedicated to developing life-saving medicines.

Tyris’ DNA-based medicines platform includes proprietary technology to

i) produce linear closed DNA, just containing the sequence of interest, and

ii) novel non-viral vectors which have no limitation in cargo capacity and enables re-administration of any gene therapy treatment; thus, overcoming current challenges in viral gene therapy, achieving more efficient and safer therapeutics for any genetic disease.

Its pipeline covers a diverse preclinical portfolio initially focused on dermatological indications as well as on renal, hematological and pulmonary therapeutic indications.

In addition, Tyris is also exploring new horizons from a DNA-based perspective (eg vaccines, CAR-Ts or MAbs). Headquarters and main R&D laboratories are located in Valencia (Spain).

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to historical information, are «forward-looking statements». These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable.

These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law. If you wish to unsubscribe from any Almirall Corporate communication click here.

In accordance with the General Data Protection Regulation and the applicable local regulations, we inform you that your personal data is processed by Almirall S.A. with registered address at Ronda del General Mitre,151, 08022, Barcelona (Spain), acting as Controller in line with the purposes indicated in our Privacy Policy.

For further information, you may consult https://www.almirall.com/privacy-policy or contact our Data Protection Officer at the e-mail address: dpo.global@almirall.com. PRNewswire is the Agency that licenses your personal data according to their privacy policy: https://gdpr.cision.com/gdpr.

At any time you can exercise your rights of access, rectification, deletion, objection, portability as well as the limitation of the processing of your data in the terms provided in the current regulations on Data Protection, by addressing the corresponding written request to our postal address (Ronda General Mitre, 151, 08022 Barcelona, Spain).

The request to exercise any of your rights must be accompanied by a copy of an official document that identifies you (ID, driver’s license or passport). Finally, we inform you that you can contact the Spanish Data Protection Agency and any other competent public bodies for any claim arising from the processing of your personal data.